A Phase 1 interventional study of ONO-7475 and ONO-4538 in Metastatic Pancreatic Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.
Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 38th largest by planned enrollment, is one of 8 that started in 2023, is one of 30 in phase 1, reaches primary completion later than 24 of the 32 other live ones, and was the 122nd registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Akeso · Sites in China
Ages 18–75
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 87 · Phase 3 8 · Phase 4 2
First in 2006; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 87 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 47 across the 130 interventional studies. Of the 70 that completed or were terminated, 27 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02207465Abramson Cancer Center at Penn MedicineA Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer | 2026-12 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-7475 · Drug: Nab-paclitaxel · Drug: Gemcitabine
Drug: ONO-7475 · Drug: ONO-4538 · Drug: Nab-paclitaxel · Drug: Gemcitabine
Specified dose on specified days
Specified dose on specified days
Also known as: Nivolumab
Specified dose on specified days
Specified dose on specified days
Dose-limiting toxicities (DLT)
Time frame: 28 days
Adverse event (AE)
Time frame: Up to 28 days after the last dose
Pharmacokinetics (Plasma concentration of ONO-7475)
Time frame: Up to Cycle16
Pharmacokinetics (Plasma concentration of ONO-4538)
Time frame: Through study completion, an average of 6 months
Anti-ONO-4538 antibody
Time frame: Through study completion, an average of 6 months
Objective Response Rate (ORR)
Time frame: Through study completion, an average of 6 months
Disease Control Rate (DCR)
Time frame: Through study completion, an average of 6 months
Overall Survival (OS)
Time frame: Through study completion, an average of 1 year
Progression-Free Survival (PFS)
Time frame: Through study completion, an average of 6 months
Duration of Response (DOR)
Time frame: Through study completion, an average of 6 months
Time to Response (TTR)
Time frame: Through study completion, an average of 6 months
Best Overall Response (BOR)
Time frame: Through study completion, an average of 6 months
Percent change in the sum diameters of the target lesions
Time frame: Through study completion, an average of 6 months
Maximum percent change in the sum diameters of the target lesions
Time frame: Through study completion, an average of 6 months
CEA
Time frame: Through study completion, an average of 6 months
CA19-9
Time frame: Through study completion, an average of 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Sep 2027, 45 months after the start.
Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 45 months is close to that.
Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tamnorzatinib · Albumin-Bound Paclitaxel · Gemcitabine
Ono Pharmaceutical Co., Ltd. →